Galecto, Inc. Common Stock
Symbol: GLTO (NASDAQ)
Company Description:
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
- Today's Open: $7.717
- Today's High: $7.717
- Today's Low: $7.3
- Today's Volume: 3.67K
- Yesterday Close: $7.73
- Yesterday High: $8.39
- Yesterday Low: $7.73
- Yesterday Volume: 98.78K
- Last Min Volume: 40
- Last Min High: $7.339
- Last Min Low: $7.315
- Last Min VWAP: $7.315
- Name: Galecto, Inc. Common Stock
- Website: https://www.galecto.com
- Listed Date: 2020-10-29
- Location: BOSTON, MA
- Market Status: Active
- CIK Number: 0001800315
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $11.30M
- Round Lot: 100
- Outstanding Shares: 1.32M
- Asset Type: CS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-09 | SCHEDULE 13D/A | View |
| 2025-09-25 | SCHEDULE 13D/A | View |
| 2025-08-05 | 10-Q | View |
| 2025-07-08 | 4 | View |
| 2025-07-08 | 4 | View |
| 2025-07-08 | 4 | View |
| 2025-06-20 | 8-K | View |
| 2025-06-20 | 4 | View |
| 2025-06-20 | 4 | View |
| 2025-06-20 | 4 | View |
| 2025-06-20 | 4 | View |
| 2025-06-20 | 4 | View |
| 2025-06-20 | 4 | View |
| 2025-05-08 | 10-Q | View |
| 2025-04-30 | ARS | View |
| 2025-04-30 | DEFA14A | View |
| 2025-04-30 | DEF 14A | View |
| 2025-04-17 | PRE 14A | View |
| 2025-03-19 | S-8 | View |
| 2025-03-19 | 10-K | View |